AngioDynamics: Business Model, SWOT Analysis, and Competitors 2026

AngioDynamics, Inc. stands as a leading company in Healthcare. Generating $307.31 million in annual revenue (growing 9.0% year-over-year) and carrying a market capitalization of $448.03 million, the company has cemented its position as a foundational player in the global Medical Instruments & Supplies landscape. Under the leadership of its leadership team, AngioDynamics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines AngioDynamics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating AngioDynamics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define AngioDynamics, Inc.'s position in the Medical Instruments & Supplies market today.

What You Will Learn

1. How AngioDynamics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering AngioDynamics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who AngioDynamics, Inc.'s main competitors are and how the company compares on key financial metrics
4. AngioDynamics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. AngioDynamics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $307.31 million annual revenue (TTM), +9.0% YoY
• Market Cap: $448.03 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 54.6%, operating margin -3.1%, net margin -9.0%
• Free Cash Flow: $300,625
• Return on Equity: -15.3% — reflects current investment phase
• Employees: 675 worldwide

Who Owns AngioDynamics, Inc.?

AngioDynamics, Inc. is publicly traded on the NMS under the ticker symbol ANGO. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of AngioDynamics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

AngioDynamics, Inc. has approximately 0.04 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $10.87 per share as of early 2026.

AngioDynamics, Inc.'s Mission Statement

AngioDynamics, Inc.'s strategic mission is aligned with its core business activities in the Medical Instruments & Supplies sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — AngioDynamics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For AngioDynamics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, AngioDynamics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does AngioDynamics, Inc. Make Money?

As of 2026, AngioDynamics, Inc. generates $307.31 million in annual revenue (growing 9.0% year-over-year), with a 54.6% gross margin and -3.1% operating margin. Market capitalization stands at $448.03 million. Here is how the company generates its revenue:

Medical Devices

One of the primary ways AngioDynamics Inc generates revenue is through the sale of medical devices. The company designs, manufactures, and sells a wide range of minimally invasive medical devices used in the treatment of vascular diseases and conditions. These devices include catheters, needles, guidewires, and other innovative tools that are essential for various medical procedures.

AngioDynamics' medical devices are used by healthcare professionals in hospitals, clinics, and ambulatory surgical centers worldwide. The company focuses on developing cutting-edge technologies that improve patient outcomes and enhance the efficiency of medical procedures. By offering a diverse portfolio of high-quality devices, AngioDynamics is able to capture market share and generate substantial revenue in the medical device industry.

Consumable Products

In addition to medical devices, AngioDynamics Inc also generates revenue through the sale of consumable products. These products are used in conjunction with the medical devices and are often disposable or single-use items. Examples of consumable products offered by the company include infusion sets, drainage systems, thrombolytic agents, and embolic materials.

Consumable products play a critical role in patient care as they are frequently used in various treatments and procedures. AngioDynamics ensures a steady stream of revenue by providing a wide range of consumables that are compatible with their medical devices. This strategy not only helps in establishing long-term relationships with customers but also allows the company to benefit from recurring purchases of consumables.

Services and Support

Apart from the sale of medical devices and consumable products, AngioDynamics Inc also generates revenue through its services and support offerings. The company provides comprehensive support to healthcare professionals by offering training, technical assistance, and maintenance services for their products.

AngioDynamics' team of experts ensures that healthcare providers are well-equipped to use their medical devices effectively and safely. They offer training programs and workshops to educate medical professionals on the proper use and handling of their products. Additionally, the company provides ongoing technical support, troubleshooting assistance, and timely maintenance services to ensure optimal performance and longevity of their devices.

By offering a range of services and support optio

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review AngioDynamics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

AngioDynamics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how AngioDynamics, Inc. creates, delivers, and captures value.

Key Partners: AngioDynamics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Medical Instruments & Supplies sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: AngioDynamics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: AngioDynamics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (675 employees), proprietary technology, and financial resources ($41.64M in cash).

Value Propositions: AngioDynamics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Medical Instruments & Supplies market.

Customer Relationships: AngioDynamics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: AngioDynamics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: AngioDynamics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: AngioDynamics, Inc.'s major costs include cost of goods sold (45.4% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 103.1% of revenue.

Revenue Streams: AngioDynamics, Inc. generates revenue through its core product and service offerings.

AngioDynamics, Inc. Competitors

AngioDynamics, Inc.'s main competitors include Becton, Dickinson and Company (BD), Medtronic plc, Boston Scientific Corporation, Cook Medical Inc, Terumo Corporation. The company operates in the Medical Instruments & Supplies segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Company	Ticker	Market Cap	Revenue (TTM)	Gross Margin
AngioDynamics, Inc.	ANGO	$448.03M	$307.31M	54.6%
Becton, Dickinson and Company (BD)	—	—	—	—
Medtronic plc	MDT	$119.41B	$35.48B	65.2%
Boston Scientific Corporation	—	—	—	—
Cook Medical Inc	—	—	—	—
Terumo Corporation	—	—	—	—

Competitive Analysis

AngioDynamics, Inc.'s competitive position in Medical Instruments & Supplies is defined by its $448.03M market capitalization and 54.6% gross margins. Key competitive advantages include brand recognition and operational scale in the Medical Instruments & Supplies market.

AngioDynamics, Inc. SWOT Analysis

A SWOT analysis examines AngioDynamics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: AngioDynamics, Inc.'s gross margin of 54.6% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -3.1% demonstrates disciplined cost management even at scale.

Weaknesses

• Competitive Scale Pressure: In the Medical Instruments & Supplies sector, larger competitors with greater economies of scale can exert pricing pressure and outspend AngioDynamics, Inc. on marketing, R&D, and distribution — limiting the company's ability to defend market share in a price-sensitive environment.
• Market Concentration Risk: Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strategic challenge.

Opportunities

• Total Addressable Market: AngioDynamics, Inc. operates in the Medical Instruments & Supplies segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for AngioDynamics, Inc.'s products and services.
• Strategic Acquisitions: With $41.64M in cash and strong free cash flow generation, AngioDynamics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. AngioDynamics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on AngioDynamics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

AngioDynamics, Inc. enters 2026 as a leading company in Healthcare, backed by $307.31 million in annual revenue and a -9.0% net profit margin. The company's 54.6% gross margins and $300,625 in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in AngioDynamics, Inc.'s core markets.

For investors and analysts, AngioDynamics, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Frequently Asked Questions

1. What does AngioDynamics, Inc. do?

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that del

2. How much revenue does AngioDynamics, Inc. make?

AngioDynamics, Inc. generated $307.31 million in annual revenue (TTM), with 9.0% year-over-year growth.

3. What is AngioDynamics, Inc.'s market cap?

AngioDynamics, Inc.'s market capitalization is approximately $448.03 million as of early 2026.

4. Is AngioDynamics, Inc. profitable?

AngioDynamics, Inc. has faced profitability challenges recently. Investors should review the latest quarterly earnings reports.

5. Who are AngioDynamics, Inc.'s competitors?

AngioDynamics, Inc. competes in the Medical Instruments & Supplies sector against companies including Becton, Dickinson and Company (BD), Medtronic plc, Boston Scientific Corporation.

6. Does AngioDynamics, Inc. pay dividends?

AngioDynamics, Inc. does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is AngioDynamics, Inc.'s stock ticker?

AngioDynamics, Inc. trades on the NMS under the ticker symbol ANGO.

8. What is AngioDynamics, Inc.'s P/E ratio?

Valuation multiples for AngioDynamics, Inc. should be verified on current financial data platforms.

9. How many employees does AngioDynamics, Inc. have?

AngioDynamics, Inc. employs approximately 675 people worldwide as of the most recent disclosure.

10. What is AngioDynamics, Inc.'s competitive advantage?

AngioDynamics, Inc.'s competitive advantages include its established brand, scale in Medical Instruments & Supplies, and track record of execution in the Healthcare sector.